THERALASE CANCER THERAPY TRIALS PROVE SAFETY OF PATENTED COMPOUNDS
TORONTO, ONTARIO--(Marketwire - Feb. 28, 2011) - Theralase Technologies Inc. (TSX VENTURE:TLT) announced today that it has successfully completed the pre-clinical safety testing in an in vivo mouse model, the next step in the commercialization of its innovative Photo Dynamic Compound (PDC) platform technology. The Theralase patented PDC's comprise a family of novel drug candidates under evaluation from the company's proprietary PDC inventory focused on oncological indications. MORE>>
